Study followed 775 grown-ups with gentle to-direct COVID-19 thought about higher danger for extreme infection.
(Thank you for reading this, don't forget to subscribe!)
Merck & Co. said Friday that its experimental COVID-19 pill reduced hospitalizations and deaths by half in people recently infected with the coronavirus and that it would soon ask health officials in the U.S. and around the world to authorize its use.
If cleared, Merck’s drug would be the first pill shown to treat COVID-19, a potentially major advance in efforts to fight the pandemic. All COVID-19 therapies now authorized in the U.S. require an IV or injection.
Merck and its partner, Ridgeback Biotherapeutics, said early results showed patients who received the drug, called molnupiravir, within five days of COVID-19 symptoms had about half the rate of hospitalization and death as patients who received a dummy pill. The study tracked 775 adults with mild-to-moderate COVID-19 who were considered higher risk for severe disease because of health problems such as obesity, diabetes or heart disease.
Among patients taking molnupiravir, 7.3 per cent were either hospitalized or died at the end of 30 days, compared with 14.1 per cent of those getting the dummy pill. There were no deaths in the drug group after that time period compared with eight deaths in the placebo group, according to Merck.
The results were released by the company and have not been peer reviewed. Merck said it plans to present them at a future medical meeting.
Health Canada has been reviewing data around molnupiravir since August as part of its rolling review of potential treatments.
Federal officials told reporters on Friday that there is no specific timeline for completing that review.
“The interest in the Merck antiviral is because of ease of use,” said chief public health officer Dr. Theresa Tam during the briefing. “And you can give it up to five days in the start of someone’s clinical course, so you have a bit of time.”
Company plans to submit data to FDA
An independent group of medical experts monitoring the trial recommended stopping it early because the interim results were so strong. Company executives said they are in discussions with the U.S. Food and Drug Administration (FDA) and plan to submit the data for review in the coming days.
“It exceeded what I thought the drug might be able to do in this clinical trial,” said Dr. Dean Li, vice-president of Merck research. “When you see a 50 per cent reduction in hospitalization or death, that’s a substantial clinical impact.”
Side-effects were reported by both groups in the Merck trial, but they were slightly more common among the group that received a dummy pill. The company did not specify the effects.
Earlier study results showed the drug did not benefit patients who were already hospitalized with severe disease.
Pfizer and BioNTech submit data to U.S. FDA for COVID-19 vaccine in younger children
FDA panel rejects broad use of COVID-19 boosters, approves extra doses for seniors, those at high risk
The U.S. has approved one antiviral drug, remdesivir, specifically for COVID-19, and allowed emergency use of three antibody therapies that help the immune system fight the virus. But all the drugs have to be given by IV or injection at hospitals or medical clinics, and supplies have been stretched by the latest surge of the delta variant.
Drug priced at $700 USD for a full course
Merck said it expects to produce 10 million courses of the treatment by the end of 2021, with more coming next year.
The company has a U.S. government contract to supply 1.7 million courses of molnupiravir at a price of $700 USD per course, or around $885 CAD.
“We are committed to providing timely access to molnupiravir globally, if it is authorized or approved, and we plan to implement a tiered pricing approach based on World Bank data that recognizes countries’ relative ability to finance their health response to the pandemic,” said Merck Canada Inc. spokesperson Mary-Jo Barr in an email to CBC News.
Several other companies, including Pfizer and Roche, are studying similar drugs that could report results in the coming weeks and months.
Merck had planned to enrol more than 1,500 patients in its late-stage trial before the independent board stopped it early. The results reported Friday included patients enrolled across Latin America, Europe and Africa. Executives estimated about 10 per cent of patients studied were from the U.S.
The announcement of positive clinical trial results sent the drugmaker’s stock price soaring on Friday while denting high-flying shares of vaccine companies and makers of other coronavirus therapies.
Merck shares jumped as much as 12.3 per cent — and hit their highest level since February 2020.